235791-24-9

Upstream product

• 6802-76-2 ethyl 2-cyano-2-cyclohexylideneacetate 
• 748118-43-6 2-benzyl-2-aza-spiro[4.5]decane-4-carboxylic acid 
• 235791-21-6 2-benzyl-2-aza-spiro<4.5>decane-carboxylic acid methyl ester 
• 235791-22-7 2-aza-spiro[4.5]decane-4-carboxylic acid methyl ester 
• 235791-23-8 2-aza-spiro<4.5>decane-2,4-dicarboxylic acid 2-benzyl ester 4-methyl ester 

Downstream Products

• 235791-25-0 (4S,1'R)-4-(1'-naphthalene-2-yl-ethylcarbamoyl)-2-aza-spiro<4.5>decane-2,4-dicarboxylic acid benzyl ester 
• 235791-26-1 (4R,1'R)-4-(1'-naphthalene-2-yl-ethylcarbamoyl)-2-aza-spiro<4.5>decane-2,4-dicarboxylic acid benzyl ester 

Relevant academic research and scientific papers

Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel

Novel substituted amino acids of formula are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders

An in vitro investigation into conformational aspects of gabapentin

Conformational analysis of constrained cyclohexane systems was pioneered fifty years ago by Barton and Hassel. We now report an investigation based on a conformational analysis of a number of novel cyclohexane based Gabapentin analogues coupled with their in vitro evaluation at the Gabapentin binding site. These data are used to propose a possible binding conformation for Gabapentin. Copyright (C) 1999 Elsevier Science Ltd.